CSL (OTCMKTS:CSLLY) Stock Price Up 8.6% – Here’s What Happened

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) traded up 8.6% on Friday . The stock traded as high as $26.61 and last traded at $26.03. 65,070 shares traded hands during trading, a decline of 80% from the average session volume of 329,145 shares. The stock had previously closed at $23.96.

Analysts Set New Price Targets

Several research analysts have recently issued reports on CSLLY shares. Royal Bank Of Canada cut shares of CSL from a “moderate buy” rating to a “hold” rating in a report on Wednesday, February 11th. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

CSL Stock Performance

The company has a 50-day moving average of $49.02 and a 200-day moving average of $58.03. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.